drugset / Trial / NCT00486031

Open-Label, Long-term Balsalziade Disodium Tablet Ulcerative Colitis Study

NCT00486031

Phase 3 Completed 443 enrolled Bausch Health Americas, Inc.
NaSingle-groupOpen-labelSupportive care

Summary

The objective of the study is to evaluate the long-term safety and tolerability of treatment with balsalazide disodium tablets in subjects who are in remission from ulcerative colitis or who have mildly to moderately active UC.

Timeline

Start
2006-10
Primary completion
2008-04
Completion
2008-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Balsalazide Small molecule 3.3 g

Indications